1. Home
  2. CAPR vs ASG Comparison

CAPR vs ASG Comparison

Compare CAPR & ASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CAPR
  • ASG
  • Stock Information
  • Founded
  • CAPR 2005
  • ASG 1986
  • Country
  • CAPR United States
  • ASG United States
  • Employees
  • CAPR N/A
  • ASG N/A
  • Industry
  • CAPR Biotechnology: Biological Products (No Diagnostic Substances)
  • ASG Investment Managers
  • Sector
  • CAPR Health Care
  • ASG Finance
  • Exchange
  • CAPR Nasdaq
  • ASG Nasdaq
  • Market Cap
  • CAPR 324.6M
  • ASG 327.8M
  • IPO Year
  • CAPR N/A
  • ASG N/A
  • Fundamental
  • Price
  • CAPR $6.18
  • ASG $5.66
  • Analyst Decision
  • CAPR Strong Buy
  • ASG
  • Analyst Count
  • CAPR 6
  • ASG 0
  • Target Price
  • CAPR $23.00
  • ASG N/A
  • AVG Volume (30 Days)
  • CAPR 1.0M
  • ASG 324.3K
  • Earning Date
  • CAPR 11-12-2025
  • ASG 01-01-0001
  • Dividend Yield
  • CAPR N/A
  • ASG 8.09%
  • EPS Growth
  • CAPR N/A
  • ASG N/A
  • EPS
  • CAPR N/A
  • ASG N/A
  • Revenue
  • CAPR $13,392,150.00
  • ASG N/A
  • Revenue This Year
  • CAPR N/A
  • ASG N/A
  • Revenue Next Year
  • CAPR $7,894.07
  • ASG N/A
  • P/E Ratio
  • CAPR N/A
  • ASG N/A
  • Revenue Growth
  • CAPR N/A
  • ASG N/A
  • 52 Week Low
  • CAPR $5.68
  • ASG $4.47
  • 52 Week High
  • CAPR $22.90
  • ASG $5.71
  • Technical
  • Relative Strength Index (RSI)
  • CAPR 40.96
  • ASG 59.81
  • Support Level
  • CAPR $6.05
  • ASG $5.48
  • Resistance Level
  • CAPR $6.42
  • ASG $5.63
  • Average True Range (ATR)
  • CAPR 0.34
  • ASG 0.08
  • MACD
  • CAPR -0.07
  • ASG 0.02
  • Stochastic Oscillator
  • CAPR 8.95
  • ASG 90.03

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

About ASG Liberty All-Star Growth Fund Inc.

Liberty All Star Growth Fund Inc is the United States based diversified, closed-end management investment company. Its investment objective is to seek long-term capital appreciation through investment in a diversified portfolio of equity securities. The company portfolio of investments consists of different industries such as consumer discretionary, consumer staples, healthcare, industrial, information technology and others.

Share on Social Networks: